Researchers generate plasma cell dataset to aid myeloma diagnosis
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
News
Blincyto approved in Europe for newly diagnosed adults with B-ALL
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of relapse in adults newly diagnosed…
Lixumistat shows promise as treatment for pancreatic cancer
Treatment with the once-daily oral therapy lixumistat, in addition to chemotherapy, slowed the growth of pancreatic cancer among participants with advanced disease in an…
Protein from blood vessel cells helps glioblastoma grow: Study
A signaling molecule released by blood vessel cells prompts cancer cells to grow and become resistant to treatment in glioblastoma, an aggressive type of…
Sempervirine stops ovarian cancer cell growth in preclinical studies
Sempervirine, a compound isolated from a plant used in traditional Chinese medicine, inhibited the growth, spread, and development of ovarian cancer cells in cell…
Sarclisa approved in EU for adults new to MM and transplant ineligible
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed with multiple myeloma who…
FDA approves Grafapex combo for bone marrow transplant with AML
The U.S. Food and Drug Administration (FDA) has approved Grafapex (treosulfan), an injectable chemotherapy, as part of the drug regimen for adults and…
Combination treatment shows promise for pancreatic cancer PDAC
Treatment with certepetide in combination with standard therapies led to stable disease in most people with a type of pancreatic cancer known as…
FDA OK’s diagnostic test to identify pediatric cancer patients for Ojemda
The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx, Foundation Medicine’s companion diagnostic test to help identify if patients with pediatric low-grade…
Calquence combo approved by FDA for untreated mantle cell lymphoma
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…
